Nick brings over 40 years of leadership in the life sciences tools and diagnostics industry, having shaped the strategic direction of companies like Agilent Technologies and Bio-Rad Laboratories. With deep expertise in chemistry, he served as President of Agilent’s Life Sciences Group, leading a $4 billion global business, including acquisitions such as Halo Genomics. At Bio-Rad, he was Life Science Group Operations Officer, driving market growth and innovation.
I have been impressed over the years by the prolific and elegant inventions which have come from Ulf Landegren’s laboratories at Uppsala University. The demonstrated ability of padlock probes and the utilization of rolling circle amplification to change the future of science is again being deployed by Rarity.
Nick is widely recognized for his strategic vision and operational excellence, with a passion for bringing new technologies to market and helping companies transition from start-up to scale-up. As an adviser to private equity firms like Summa Equity, Nordic Capital and Sciety, he has guided investments in companies such as Olink, where he played a key role in its sale to Thermo Fisher for 34 billion SEK. His board experience spans several innovative companies, including 908 Devices, The Binding Site, and Velsera.
“Having Nick onboard as an advisor is fantastic. This is not the first time Nick is working with padlock-technologies and his commercial experience from Halo Genomics and Olink are particularly relevant in crafting and refining our commercial and funding strategies“
– Linus Bosaeus, CEO Rarity Bioscience
